Katy Spink Talks with Precision Medicine Online - 2026

March 2, 2026

Categories

In the News

Publications

Press Room

‍Can Rare Disease Drugmakers Trust FDA's Promises of Flexibility Amid String of Rejections?

Mar 02, 2026

By Jessica Kim Cohen

NEW YORK – While the US Food and Drug Administration touts new regulatory flexibility for rare disease drugs, recent rejections of regulatory applications are giving sponsors "whiplash" from mixed signals, biotech industry observers say.

Continue Reading Behind Paywall Here: https://www.precisionmedicineonline.com/regulatory-news-fda-approvals/can-rare-disease-drugmakers-trust-fdas-promises-flexibility-amid

Sara Mills co-authors "Process evolution in C and GT from discovery to commercialization"

Anthony offers insights with Endpoints News

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Why is Demand & Supply Planning in the Life Sciences so Difficult?

Stay Informed

Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

We respect your privacy. Unsubscribe at any time. We will never sell your information.